Esperion Therapeutics, Inc.: 10-Q filed 2013-11-06
What Esperion Therapeutics, Inc. reported in its quarterly report filed 2013-11-06 (fiscal Q3 2013): 23 published measures, 72 facts as tagged in accession 0001104659-13-081698.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2013-11-06
- Fiscal period
- fiscal Q3 2013
- Accession
- 0001104659-13-081698 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Esperion Therapeutics, Inc. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-09-30 | 86,575,812 | USD | |
| At 2012-12-31 | 7,312,441 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-09-30 | 3,342,956 | USD | |
| At 2012-12-31 | 24,702,144 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-09-30 | 83,232,856 | USD | |
| At 2012-12-31 | -41,364,703 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-09-30 | 71,895,828 | USD | |
| At 2012-12-31 | 6,511,521 | USD | |
| At 2012-09-30 | 3,165,074 | USD | |
| At 2011-12-31 | 1,571,084 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-07-01 to 2013-09-30 | -5,238,434 | USD | 92 |
| 2013-01-01 to 2013-09-30 | -16,398,687 | USD | 273 |
| 2008-01-22 to 2013-09-30 | -58,373,712 | USD | 2079 |
| 2012-07-01 to 2012-09-30 | -3,351,274 | USD | 92 |
| 2012-01-01 to 2012-09-30 | -8,966,380 | USD | 274 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-01-01 to 2013-09-30 | 18,203 | USD | 273 |
| 2008-01-22 to 2013-09-30 | 285,762 | USD | 2079 |
| 2012-01-01 to 2012-09-30 | 10,668 | USD | 274 |
Income tax expense or benefit
Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-07-01 to 2013-09-30 | 0 | USD | 92 |
| 2013-01-01 to 2013-09-30 | 0 | USD | 273 |
| 2012-07-01 to 2012-09-30 | 0 | USD | 92 |
| 2012-01-01 to 2012-09-30 | 0 | USD | 274 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-09-30 | 78,749 | USD | |
| At 2012-12-31 | 120,210 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-01-01 to 2013-09-30 | 673,244 | USD | 273 |
| 2008-01-22 to 2013-09-30 | 930,352 | USD | 2079 |
| 2012-01-01 to 2012-09-30 | 60,578 | USD | 274 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-07-01 to 2013-09-30 | -5,406,823 | USD | 92 |
| 2013-01-01 to 2013-09-30 | -13,022,682 | USD | 273 |
| 2008-01-22 to 2013-09-30 | -51,727,372 | USD | 2079 |
| 2012-07-01 to 2012-09-30 | -2,990,249 | USD | 92 |
| 2012-01-01 to 2012-09-30 | -8,043,713 | USD | 274 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-09-30 | 72,964,046 | USD | |
| At 2012-12-31 | 7,138,406 | USD |
Interest expense
Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-01-01 to 2013-09-30 | 936,580 | USD | 273 |
| 2008-01-22 to 2013-09-30 | 4,320,696 | USD | 2079 |
| 2012-07-01 to 2012-09-30 | 361,426 | USD | 92 |
| 2012-01-01 to 2012-09-30 | 925,021 | USD | 274 |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-09-30 | 3,342,956 | USD | |
| At 2012-12-31 | 17,173,299 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-09-30 | 1,944,604 | USD | |
| At 2012-12-31 | 476,277 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-07-01 to 2013-09-30 | 5,406,823 | USD | 92 |
| 2013-01-01 to 2013-09-30 | 13,022,682 | USD | 273 |
| 2008-01-22 to 2013-09-30 | 51,971,851 | USD | 2079 |
| 2012-07-01 to 2012-09-30 | 2,990,249 | USD | 92 |
| 2012-01-01 to 2012-09-30 | 8,043,713 | USD | 274 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-09-30 | 15,335,223 | shares | |
| At 2012-12-31 | 346,478 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-09-30 | 141,585,222 | USD | |
| At 2012-12-31 | 609,976 | USD |
Accumulated other comprehensive income or loss
Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-09-30 | 5,989 | USD |
Comprehensive income or loss
Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-07-01 to 2013-09-30 | -5,232,445 | USD | 92 |
| 2013-01-01 to 2013-09-30 | -16,392,698 | USD | 273 |
| 2012-07-01 to 2012-09-30 | -3,351,274 | USD | 92 |
| 2012-01-01 to 2012-09-30 | -8,966,380 | USD | 274 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-07-01 to 2013-09-30 | 1,924,150 | USD | 92 |
| 2013-01-01 to 2013-09-30 | 4,346,994 | USD | 273 |
| 2008-01-22 to 2013-09-30 | 15,796,690 | USD | 2079 |
| 2012-07-01 to 2012-09-30 | 533,837 | USD | 92 |
| 2012-01-01 to 2012-09-30 | 1,699,867 | USD | 274 |
Depreciation expense
Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-01-01 to 2013-09-30 | 59,664 | USD | 273 |
| 2008-01-22 to 2013-09-30 | 1,436,835 | USD | 2079 |
| 2012-01-01 to 2012-09-30 | 106,901 | USD | 274 |
Other nonoperating income or expense
Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-07-01 to 2013-09-30 | 168,389 | USD | 92 |
| 2013-01-01 to 2013-09-30 | 147,440 | USD | 273 |
| 2008-01-22 to 2013-09-30 | 228,854 | USD | 2079 |
| 2012-07-01 to 2012-09-30 | 401 | USD | 92 |
| 2012-01-01 to 2012-09-30 | 2,354 | USD | 274 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-01-01 to 2013-09-30 | 1,299,100 | USD | 273 |
| 2008-01-22 to 2013-09-30 | 1,775,377 | USD | 2079 |
| 2012-01-01 to 2012-09-30 | -486,537 | USD | 274 |
Inspect the source
- Entity
- Esperion Therapeutics, Inc. / CIK 0001434868
- Captured
- 2026-09-21T17:19:05.322Z
- SEC response SHA-256
c855d6a6c2d879a88675aebb590fdc9935826605a25a04ffeec1282218bce6bf
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001434868.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))